Baxter-Funded Panel Seeks To Solve White Particulate Matter Mystery
This article was originally published in The Gray Sheet
Executive Summary
Baxter expects to share with FDA by May results from an expert panel formed to investigate unidentified white particulate matter found in U.S. blood bags
You may also be interested in...
Blood inspection guidance
FDA is working with Baxter, American Red Cross, CDC and state health authorities to investigate reports of white particulate found in approximately 100 Baxter blood bags. Interim guidance on visual inspection methods of all blood and blood components will be issued shortly, FDA notes Feb. 7, recommending Red Cross procedures such as "placing the bag, label down, on a flat counter undisturbed for 10 minutes and then performing a visual examination for particles." FDA reports receiving a "small number of adverse reports in patients who had also received transfusions utilizing such bags, including one fatality." Baxter said Feb. 3 the particulate is "blood-derived in nature [and] likely a very small fibrin clot containing white blood cells and platelets." Red Cross quarantined 70% of the blood inventory in its southern region and shipped approximately 3,000 new units to Atlanta and 500 units to the Tennessee Valley...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.